Changes in direct markers of liver fibrosis in patients with steatohepatitis non-alcoholic and alcoholic origin on the background of obesity and pathology of the biliary tract
DOI:
https://doi.org/10.14739/2310-1210.2017.2.95682Keywords:
matrix metalloproteinase-1, laminin, hepatocyte growth factor, liver fibrosis, non-alcoholic steatohepatitis, alcoholic steatohepatitis, obesityAbstract
The aim of this work is to investigate the direct markers of liver fibrosis (LF) in patients with steatohepatitis non-alcoholic and alcoholic origin in combination with obesity (OB) and pathology of the biliary tract (BT).
Materials and Methods. We examined 30 patients with steatohepatitis of different etiology, in 15 patients of them was non-alcoholic steatohepatitis (NASH) and 15 had alcoholic steatohepatitis (ASH). The control group consisted of 15 practically healthy persons (PHP). Direct markers of fibrosis – matrix metalloproteinase-1 (MMP-1), laminin (LN), hepatocyte growth factor (HGF) were determined by ELISA.
Results. In all groups of patients we found a significant decrease in MMP-1 1.7 times in NASH (p < 0.001) and 1.6 times at ASH in comparison with the reference values of PHP (p < 0.05). It has been defined the increase in the content of LN 1.8 times in the NASH group in relation to PHP (p < 0.001). A high level of LN was observed in the group of ASH and increased in 2.2 times compared with PHP (p < 0.001) and 1.2 times compared with NASH patients (p < 0.001). The content of HGF was reduced compared with control 1.5-fold and 1.6-fold respectively, in NASH and ASH (p < 0.001 for all comparisons).
Conclusions. It has been established that reduced levels of MMP-1 and increased levels of LN indicated the progression of LF in patients with steatohepatitis with more pronounced progression during the ASH. It has been proved that the elevated level of LN and reduced level of HGF, coupled with the presence of non-alcoholic or alcoholic factor, had made a significant contribution to the development of LF in patients with NASH and ASH in combination with theOB and pathology of BT.
References
Yagmur, V., Kudryavceva, V., Yagmur, S., et al. (2012). Markery fibrogeneza i ursosan pri khronicheskikh diffuznykh zabolevaniyakh pecheni [Markers of fibrogenesis and Ursosan in chronic diffuse liver diseases] Proceedings of the 17th Russian Congressю Rossijskij zhurnal gastroe´nterologii, gepatologii, kolonoproktologii, 2(XXІІ), 75. [in Russian].
Chrostek, L., & Panasiuk, A. (2014). Liver fibrosis markers in alcoholic liver disease. World J Gastroenterol, 20(25), 8018–23. doi: 10.3748/wjg.v20.i25.8018.
Fitzpatrick, E., & Dhawan, A. (2014). Noninvasive biomarkers in non-alcoholic fatty liver disease: Current status and a glimpse of the future. World J Gastroenterol, 20(31), 10851–63. doi: 10.3748/wjg.v20.i31.10851.
Sowa, J. P., Atmaca, Ö., Kahraman, A., Schlattjan, M., Lindner, M., Sydor, S., et al. (2014). Non-invasive separation of alcoholic and non-alcoholic liver disease with predictive modeling. PLoS One, 9(7), e101444. doi: 10.1371/journal.pone.0101444.
Mahmoud, A. A., Bacir, A. S., & Shabana, S. S. (2012). Serum TGF-β, Serum MMP-1, and HOMA-IR as non-invasive predictors of fibrosis in Egyptian patients with NAFLD. Saudi J. Gastroenterology, 18(5), 327–333. doi: 10.4103/1319-3767.101132.
Goodnough, J. B., Ramos, E., Nemeth, E., & Ganz, T. (2012). Inhibition of hepcidin transcription by growth factors. Hepatology, 25(10), 1002–1015. doi: 10.1002/hep.25615.
(2005) Nakaz Ministerstva okhorony zdorovia Ukrainy «Pro zatverdzhennia protokoliv nadannia medychnoi dopomohy khvorym za spetsialnistiu Hastroenterolohiia» vid 13.06.2005 r. №271. [Order of the Ministry of Health of Ukraine On approval of protocols of medical care to patients in the specialty of Gastroenterology from June 13. 2005, №271] [in Ukrainian].
(2014) Nakaz Ministerstva okhorony zdorovia Ukrainy «Unifikovanyi klinichnyi protokol pervynnoi, vtorynnoi (spetsializovanoi) medychnoi dopomohy “Nealkoholnyi steatohepatyt” ta “Alkoholnyi hepatyt”» vid 06.08.2014 r. №826. [Order of the Ministry of Health of Ukraine Unified clinical protocol of primary, secondary (specialized) medical care "Nonalcoholic steatohepatitis", "Alcoholic hepatitis" from August 6. 2014, №826] [in Ukrainian].
Toouli, J., Fried, M., & Ghafoor, K.A. (2009). Obesity World Gastroenterology Organisation Global Guideline.
Lefkovitsa, I., & Pernisa, B. (1988) Immunologicheskie metody 3. Metody issledovanij v immunologii [Immunological methods 3. Research methods in immunology]. Moscva: Mir. [in Russian].
Downloads
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)
